Key statistics
On Friday, Acrivon Therapeutics Inc (ACRV:NMQ) closed at 1.63, 55.24% above the 52 week low of 1.05 set on Jun 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.59 |
|---|---|
| High | 1.71 |
| Low | 1.59 |
| Bid | 1.61 |
| Offer | 1.65 |
| Previous close | 1.58 |
| Average volume | 731.14k |
|---|---|
| Shares outstanding | 31.56m |
| Free float | 25.07m |
| P/E (TTM) | -- |
| Market cap | 51.43m USD |
| EPS (TTM) | -2.13 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
- Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
- UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
- Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
- Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
- Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
- Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
- Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
More ▼
